Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 13, 2019

Sunovion says SEP-363856 improved schizophrenia symptoms

Sunovion Pharmaceuticals has announced positive findings from the SEP361-202 open-label extension study of SEP-363856 in patients with schizophrenia.

Sunovion Pharmaceuticals has announced positive findings from the SEP361-202 open-label extension study of SEP-363856 in patients with schizophrenia.

Discovered in alliance with PsychoGenics, SEP-363856 is an agonist of trace amine-associated receptor 1 (TAAR1) and serotonin 1A (5-HT1A) receptors. The drug is being developed to treat schizophrenia and psychosis associated with Parkinson’s disease.

In May this year, the Food and Drug Administration (FDA) awarded breakthrough therapy designation for SEP-363856 to treat schizophrenia.

The open-label extension study assessed the long-term safety and effectiveness of the drug over 26 weeks in 157 patients who completed the four-week, double-blind treatment phase of SEP361-201 study.

About 66% of participants completed the open-label study and 11.5% discontinued because of an adverse event.

Results showed that SEP-363856 was generally safe and well-tolerated, without any clinically meaningful changes in metabolic parameters or prolactin levels.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

In addition, the drug led to clinically meaningful improvements on the efficacy measures of Positive and Negative Syndrome Scale (PANSS) total score, the Clinical Global Impression Scale – Severity (CGI-S) score and the Brief Negative Symptom Scale (BNSS) total score.

Disease exacerbation, headache, insomnia and anxiety occurred in at least 5% of patients.

Sunovion Pharmaceuticals Psychiatry global clinical research head Justine Kent said: “The results of our six-month, open-label extension study in patients living with schizophrenia demonstrate that SEP-363856 has an excellent long-term safety profile, with continued, clinically meaningful improvement seen in the PANSS total score.

“We look forward to swiftly progressing our global Phase III clinical studies of SEP-363856 in both adult and adolescent patients with schizophrenia.”

Schizophrenia is a chronic and severely disabling brain disorder that causes hallucinations, delusions, disorganised thinking, social withdrawal and cognitive impairment, among other symptoms.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy